Author Affiliations: Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California.
Goldberg LH, Firoz BF, Weiss GJ, Blaydorn L, Jameson G, Von Hoff DD. Basal cell nevus syndrome: a brave new world. Arch Dermatol. 2010;146(1):17-19.
While most basal cell carcinomas (BCCs) are amenable to resection, surgical intervention is impractical for patients with metastatic or locally invasive BCCs or cancer predisposition syndromes, such as basal cell nevus syndrome. Until now, treatments for these nonsurgical candidates met with limited efficacy. The causal role of aberrant hedgehog signaling in BCCs has led to the recent exploration of hedgehog pathway inhibitors as a targeted therapy, and, as shown by Goldberg et al last year, the smoothened antagonist GDC-0449 [2-chloro-N- (4-chloro-3-[pyridin-2-yl]phenyl)-4-(methylsulfonyl)benzamide] can achieve clinical regression in basal cell nevus syndrome. Since Goldberg and colleagues' article was published, GDC-0449 has demonstrated efficacy against advanced BCCs and metastatic medulloblastoma, and hedgehog pathway inhibitors are currently under clinical investigation for several other lethal cancers. Hedgehog pathway inhibitors offer a new adjuvant medical therapy for advanced and, if trials demonstrate effectiveness, early-stage BCCs.
From August 2009, through August 2010, this article was viewed 1858 times on the Archives of Dermatology Web site.
Contact Dr Oro at Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA 94305 (email@example.com).
Financial Disclosure: The authors have participated in a Genentech-sponsored trial for GDC-0449.
This article was corrected for errors on October 17, 2011.
Gomezospina N, Oro AE. Top-Accessed Article: Basal Cell Nevus Syndrome. Arch Dermatol. 2011;147(10):1213. doi:10.1001/archdermatol.2011.304